Cyr61/CCN1 Displays High-Affinity Binding to the Somatomedin B \(^{1–44}\) Domain of Vitronectin

Ivo M. B. Francischetti\(^1,^{*}\), Michalis Kotsyfakis\(^3\), John F. Andersen\(^1\), Jan Lukszo\(^2\)

\(^1\) Section of Vector Biology, Laboratory of Malaria and Vector Research, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America, \(^2\) Peptide Synthesis and Analysis Laboratory, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America, \(^3\) Institute of Parasitology, Biology Centre, National Academy of Sciences of Czech Republic, Ceske Budejovice, Czech Republic

Abstract

**Background:** Cyr61 is a member of the CCN (Cyr61, connective tissue growth, NOV) family of extracellular-associated (matricellular) proteins that present four distinct functional modules, namely insulin-like growth factor binding protein (IGFBP), von Willebrand factor type C (vWF), thrombospondin type 1 (TSP), and C-terminal growth factor cysteine knot (CT) domain. While heparin sulphate proteoglycans reportedly mediate the interaction of Cyr61 with the matrix and cell surface, the role of other extracellular associated proteins has not been revealed.

**Methods and Findings:** In this report, surface plasmon resonance (SPR) experiments and solid-phase binding assays demonstrate that recombinant Cyr61 interacts with immobilized monomeric or multimeric vitronectin (VTNC) with \(K_D\) in the nanomolar range. Notably, the binding site for Cyr61 was identified as the somatomedin B domain (SMTB \(^{1–44}\)) of VTNC, which mediates its interaction with PAI-1, uPAR, and integrin \(\alpha_v\beta_3\). Accordingly, PAI-1 outcompetes Cyr61 for binding to immobilized SMTB \(^{1–44}\), and Cyr61 attenuates uPAR-mediated U937 adhesion to VTNC. In contrast, isothermal titration calorimetry shows that Cyr61 does not display high-affinity binding for SMTB \(^{1–44}\) in solution. Nevertheless, competitive ELISA revealed that multimeric VTNC, heat-modified monomeric VTNC, or SMTB \(^{1–44}\) at high concentrations attenuate Cyr61 binding to immobilized VTNC, while monomeric VTNC was ineffective. Therefore, immobilization of VTNC exposes cryptic epitopes that recognize Cyr61 with high affinity, as reported for a number of antibodies, \(\beta\)-endorphin, and other molecules.

**Conclusions:** The finding that Cyr61 interacts with the SMTB \(^{1–44}\) domain suggests that VTNC represent a point of anchorage for CCN family members to the matrix. Results are discussed in the context of the role of CCN and VTNC in matrix biology and angiogenesis.

Introduction

The Cyr61/CCN1 gene encodes a matricellular protein that belongs to the CCN family comprising CCN1/Cyr61; CCN2/CTGF (connective tissue growth factor); CCN3/NOV (nephroblastoma overexpressed); and CCN4/6/WISP1–3 (Wnt-inducible secreted proteins) \([1–3]\). Members of the CCN family have emerged as dynamically expressed, extracellular matrix-associated proteins that play critical roles in cardiovascular and skeletal development, injury repair, fibrotic diseases, and cancer. CCNs typically comprise four conserved cysteine-rich modular domains, with an N-terminal secretory peptide followed by four conserved domains with sequence homologies to insulin-like growth factor binding proteins (IGFBPs), von Willebrand factor type C repeat (vWC), thrombospondin type I repeat (TSP), and a carboxyl-terminal (CT) domain that contains a cysteine knot motif \([1–3]\). A series of ligands, including heparin sulphate proteoglycans (HSPG), growth factors, and integrins, reportedly interact with different domains of CCN members—these interactions may contribute to their unique activity and functions \([1–3]\).

Similarly to CCN family members, the IGFBP family members are multidomain proteins with distinct cysteine-rich N- and C-terminal domains linked by a variable linker region. The family consists of six IGFBPs (1–6) that bind insulin growth factors (IGFs) with high affinity (dissociation constant \([K_D]\) 0.1 nM) to control their transport, localization, and metabolic breakdown \([4]\). Interestingly, the IGFBP domain of the CCN proteins shares strong sequence similarity to the N-terminal domain of traditional IGFBPs; this similarity has resulted in some CCN proteins being classified as additional IGFBPs or as IGFBP-related proteins \([4]\). Despite the similarity with the N-terminal domains, the CCN proteins bind IGF poorly, in the order of 100-fold lower affinity than the traditional IGFBPs. Recent evidence also indicates that some IGFBPs have actions that are IGF independent. For example, IGFBP-5 promotes cell growth and osteocalcin expression in IGF-I knockout mice \([4–6]\) and displays high-affinity binding to vitronectin (VTNC) in an insulin growth factor-1 (IGF-I) independent manner \([7]\).

VTNC belongs to a group of adhesive glycoproteins that play key roles in the attachment of cells to their surrounding.
extracellular matrix (ECM) [8–11]. It plays a significant role in a number of physiologic processes such as cell adhesion, cell migration, wound healing, and regulation of the plasminogen activation (PA) system [12,13]. In plasma, VTNC exists in a native, monomeric conformation, while during tissue injury or tumor growth, VTNC is recruited from the plasma into the extracellular matrix and assumes an active conformation through multimerization [14]. Many of the biologic functions of VTNC are mediated through interaction of the N-terminus (1–44 amino acids) somatomedin B domain (SMTB 1–44) of VTNC with a wide variety of ligands [15–22]. For example, it promotes cell attachment, spreading, and migration through interaction with cellular receptor integrins such as αvβ3 and αvβ5 [9]. VTNC also contributes to cell adhesion by binding to urokinase-type plasminogen activator receptor (uPAR) on the cell surface [18,23,24]. Further, VTNC interacts with high affinity to 1 plasminogen activator inhibitor (PAI-1), the primary serine protease inhibitor (serpin) of both tissue- and urokinase-type plasminogen activators, leading to attenuation of fibrinolysis [12,13].

In this paper, we hypothesize that members of the CCN family of proteins might interact with VTNC. Our in vitro results demonstrate that recombinant Cyr61 interacts with high affinity to immobilized multimeric or monomeric VTNC. Further, the binding site for Cyr61 was identified as the SMTB 1–44 domain of VTNC. Our results suggest that VTNC operates as an anchor for Cyr61, possibly modulating its biologic functions.

Results

Identification of Cyr61 as a Ligand for VTNC

The CCN family of proteins is composed of six members, including Cyr61, CTGF, NOV, and WISP-1, -2, and -3. Figure 1A shows that they typically present four distinct functional modules, namely insulin-like growth factor (IGFBP), von Willebrand factor type C (vWF), thrombospondin type 1 (TSP), and C-terminal growth factor cysteine knot (CT) domain. Each of the four modules is thought to act both independently and interdependently; the ligands identified for each domain are specified in Figure 1A [1–3]. Figure 1B shows that the N-terminus of Cyr61 and other CCN family members display high sequence similarity to the IGFBP-3 and -5, which reportedly bind to VTNC with high affinity [7]. To verify whether IGFBPs and Cyr61 binds to VTNC, recombinant proteins were first assessed by SDS-PAGE to confirm correct molecular weight and purity (Figure 1, C and D). Cyr61 biologic activity has been determined by dose-dependent stimulation of the proliferation of 3T3 cells with a corresponding biologic activity has been determined by dose-dependent stimulation of the proliferation of 3T3 cells with a corresponding dose of 50% cell proliferation (ED50) of 2–3 µg/ml according to the manufacturer (Peprotech Inc. certificate of analysis).

Multimeric VTNC was then immobilized (2851.4 resonance units [RU]) in a CM5 chip for screening assays and different ligands tested for binding using surface plasmon resonance (SPR). Figure 1E shows that only IGFBP-3 and -5 (100 nM) interact with VTNC as reported [7], and the same was observed for Cyr61, while IGFBP-1, -2, and 4 were ineffective. To verify binding and specificity by a second technique, solid-phase binding assays were optimized as described in Materials and Methods. Figure 1F demonstrates that Cyr61 binds to multimeric VTNC, which was detectable at levels of VTNC as low as 5 ng/well (not shown). Cyr61 also reproducibly interacted with other matrix proteins such as collagen and laminin, although at 15–20% of the value obtained for VTNC. Cyr61 binding to unrelated immobilized proteins such as ixolaris (a recombinant tissue factor pathway inhibitor from tick saliva) [25], which served as a control, was near basal levels.

An important control for the experiments described here has been to investigate the specificity of Cyr61 also by checking its effects using a series of enzymes that may play a role in tissue homeostasis. Figure 1G demonstrates that Cyr61 displays no inhibitory properties toward a panel of coagulation factors including thrombin, Factor Xa, Factor XIIa, and kallikrein. It is also devoid of inhibitory activity for uPA, trypsin, chymotrypsin, and other enzymes involved in inflammation such as elastase, chymase, and matryptase [26]. These results indicate that our preparation of Cyr61 binds to VTNC with high affinity, although it may also interact with other matrix proteins such as collagen and laminin.

Cyr61 Is a High-Affinity Ligand for Immobilized VTNC

To further characterize Cyr61 binding to VTNC, kinetics were performed using SPR experiments that detect real-time biomolecular interactions. For this set of experiments, VTNC was immobilized at low levels (~600 RU) to avoid mass transfer effects [27]. An appropriate equation to fit the experimental results was chosen based on the residuals and calculated iC2 for each interaction. Sensorgrams collected for Cyr61 interaction with monomeric (Figure 2A) or multimeric (Figure 2B) VTNC display biphasic kinetics that fit best to a two-state reaction (conformational change) mechanism with two on- and off-rate constants yielding KD 5.66 and 27.55 nM, respectively. SPR experiments also suggest that Cyr61:VTNC complex formation displays a more complex binding mechanism and involves one binding site with a two-step reaction where an encounter complex, (Cyr61:VTNC)*, is observed before reaching the final complex state. Table 1 summarizes the kinetic findings.

Figure 2, C and D, respectively show the results for Cyr61 interaction with immobilized monomeric or multimeric VTNC estimated by solid-phase binding assays. Binding occurs in a dose-dependent manner, is saturable, and has an apparent (app) KD 26.33±5.31 nM for monomeric VTNC and 22.62±4.73 nM for multimeric VTNC. Data fitted with Langmuir equation for one binding site yield a 1 value (0.8927) comparable to two binding sites (0.9189). In addition, app KD value calculated by Langmuir equation is in close agreement with the KD calculated from the SPR data, which were fitted using a two-state model that takes into account one site (Table 1). Figure 2, E and F, respectively show semi-log transformation of data presented in Figure 2, C and D, which display a pattern suggestive of multiple binding sites or alternatively, due to heterogeneity in Cyr61 preparation or in immobilization of VTNC. In some experiments, Cyr61 interaction with multimeric VTNC was performed in the presence of TBS 0.4% Tween supplemented with 0.5% gelatin to exclude nonspecific interaction, and very similar results were obtained when compared to TBS 0.4% Tween only (app KD 36.5±9.6 nM).

The SMTB 1–44 Domain Is a High-Affinity Binding Site for Cyr61

The SMTB 1–44 domain of VTNC comprises the first 44 amino acids of the protein and mediates its interaction with PAI-1, uPAR, and integrin αvβ3 [15–20]. In an attempt to verify whether Cyr61 binds to SMTB 1–44 domain, the peptide was synthesized, refolded, and purified to homogeneity as shown in Figure 3A. Mass spectrometry analysis of the fraction containing the SMTB 1–44 domain indicates a molecular mass of 5,003.00 Da., which is in agreement with the theoretical mass of 5,003.5 Da. for the peptide with eight oxidized cysteines (Figure 3B). A series of control experiments were performed to demonstrate that SMTB 1–44 was functionally folded. In the first set, gel-filtration chromatography was employed in an attempt to demonstrate PAI-1-SMTB 1–44 binding.
Figure 1. Cyr61 binds to VTNC. (A) Structure of CCN family members. CCN1 (Cyr61, represented in the figure), CCN2 (CTGF), CCN3 (NOV), CCN4 (WISP-1), CCN5 (WISP-2), and CCN6 (WISP-3) have a shared structure consisting of a secretory signal peptide (SP), an IGFBP domain (Module I), a von Willebrand type C domain (vWC, Module II), a thrombospondin-1 domain (TSP, Module III) and a cysteine knot (CT, Module IV) domain. Domains are linked by hinge regions susceptible to protease cleavage. Modified from reference [3]. (B) Clustal alignment of CCN family members with IGFBP-3 and -5 indicates several conserved residues (*). (C) and (D) SDS-PAGE for IGFBP-1 to -5, and Cyr61, respectively. Two μg of proteins were loaded in a 4–12% NU-PAGE gel, which was Coomassie blue stained. (E) SPR experiments: proteins (100 nM) were used as analytes for immobilized VTNC. Binding levels at stability was used as a value for comparison. RU, resonance units. (F) Specificity of Cyr61 (30 nM) tested by solid-phase binding assays: proteins were immobilized as the following densities/well: VTNC (25 ng), fibrilar collagen (50 ng), ixolaris (75 ng), soluble collagen and laminin (100 ng), followed by incubation with Cyr61 (30 nM). Bound-Cyr61 was identified using anti-Cyr61 monoclonal antibody. (G) Cyr61 does not inhibit enzyme activity. Cyr61 (300 nM) was incubated with different enzymes and fluorogenic substrate hydrolysis was followed as indicated in Materials and Methods. SEM are not depicted but were less than 5% (n = 3).

doi:10.1371/journal.pone.0009356.g001
interactions in solution. Figure 3C shows that SMTB1–44 applied to
the column elutes at 1.38 ml (blue line), while PAI-1 elutes at
1.11 ml (green line). As the concentration of PAI-1 increases in a
mixture containing a fixed concentration of SMTB1–44, the peak
corresponding to SMTB1–44 decreases, and a peak corresponding
to PAI-1-SMTB1–44 complex formation elutes at 1.06 ml (red and
blacks lines).

In a second set of control experiments, the SMTB1–44-PAI-1
interaction was analyzed by SPR where SMTB 1–44 was
immobilized by amine coupling and PAI-1 served as the analyte
[15–20]. Figure 3D shows that PAI-1 binds to SMTB1–44 with a
$K_D$ in the pM range ($\approx 40$ pM; Table 2) as previously reported
[15]. Together, these controls validated the use of synthetic SMTB
1–44 for additional experimentation. Accordingly, Figure 4E
illustrates sensorgrams for Cyr61 interaction with SMTB 1–44.
Data were better described as a two-state conformational change,
which yields a $K_D$ of $\approx 10$ nM. In contrast, binding was not
interactions in solution. Figure 3C shows that SMTB1–44 applied to
the column elutes at 1.38 ml (blue line), while PAI-1 elutes at
1.11 ml (green line). As the concentration of PAI-1 increases in a
mixture containing a fixed concentration of SMTB1–44, the peak
corresponding to SMTB1–44 decreases, and a peak corresponding
to PAI-1-SMTB1–44 complex formation elutes at 1.06 ml (red and
blacks lines).

In a second set of control experiments, the SMTB1–44-PAI-1
interaction was analyzed by SPR where SMTB 1–44 was
immobilized by amine coupling and PAI-1 served as the analyte
[15–20]. Figure 3D shows that PAI-1 binds to SMTB1–44 with a
$K_D$ in the pM range ($\approx 40$ pM; Table 2) as previously reported
[15]. Together, these controls validated the use of synthetic SMTB
1–44 for additional experimentation. Accordingly, Figure 4E
illustrates sensorgrams for Cyr61 interaction with SMTB 1–44.
Data were better described as a two-state conformational change,
which yields a $K_D$ of $\approx 10$ nM. In contrast, binding was not

| Table 1. Kinetics of Cyr61 interactions with VTNC and
| SMTB 1–44. |
|---|---|---|---|---|---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n

Responses were obtained by injecting Cyr61 over immobilized VTNC or
SMTB 1–44 for 90 seconds at a flow rate of 30 µl/minute. Data fitting using
two-site binding model (conformational change). Kinetic values obtained from
the sensorgrams are presented in Figure 2, C and D, and in Figure 3E.

doi:10.1371/journal.pone.0009356.t001
Figure 3. Cyr61 displays high-affinity binding to SMTB $^{1-44}$ domain. (A) SMTB $^{1-44}$ was chemically synthesized and purified by reverse-phase chromatography. (B) Mass spectrometry for the synthetic peptide shows the expected mass for SMTB $^{1-44}$. (C) Gel-filtration chromatography shows complex formation between PAI-1 and SMTB $^{1-44}$ was performed as in Materials and Methods. (D) SPR experiments. Sensorgrams shows PAI-1 (in nM: a, 1.8; b, 0.9; c, 0.45; d, 0.225; e, 0.11) binding to immobilized SMTB $^{1-44}$ domain. (E) Sensorgrams show Cyr61 (in nM: a, 12.5; b, 6.25; c, 3.1) binding to the SMTB $^{1-44}$ domain. Data were fitted using global two-state binding model. RU, resonance units. (F) Solid-phase binding assay. Cyr61 (0–1 μM) was incubated with immobilized SMTB $^{1-44}$ and binding estimated with anti-Cyr61 monoclonal antibody, followed by alkaline phosphatase-labeled anti-mouse secondary antibody and appropriate substrate as described in Materials and Methods. (G) Semi-log transformation of the results presented in (F). The (apparent) $K_d$ values for Cyr61/ SMTB $^{1-44}$ interactions were calculated by nonlinear regression analysis of the binding data according to the Langmuir isotherm equation. (H) Competition experiments. Cyr61 (30 nM) was incubated with 0, 50, and 500 nM PAI-1, or 500 nM iXolaris. Mixtures were added to SMTB $^{1-44}$-coated wells and incubated for 90 minutes. SMTB $^{1-44}$-bound Cyr61 was estimated as in (E). Experiments were performed in quadruplicate or quintuplicate ($n = 3$).
observed when ixolaris was used as the control analyte (data not shown).

Interaction was verified by solid-phase binding experiments. Figure 3, F and G, demonstrates a dose-dependent interaction of Cyr61 with SMTB1–44 that is saturable and has calculated 

\[ K_D = 27.23 \pm 3.29 \text{ nM} \]

Because PAI-1 displays high affinity and specificity for the SMTB 1–44 domain of VTNC [15–20] competition experiments were performed using a mixture containing Cyr61 and increasing concentrations of stable mutant PAI-1. Figure 3H shows that PAI-1 dose-dependently outcompetes with Cyr61 for binding to SMTB1–44; 500 nM PAI-1 resulted in more than 80% inhibition. In contrast, ixolaris (500 nM) did not affect Cyr61 interaction with SMTB1–44. Very similar results were obtained when PAI-1 was incubated first with SMTB 1–44 immobilized in the plate, followed by washing and addition of Cyr61 (not shown).

Cyr61 Does Not Display High-Affinity Binding to SMTB 1–44 in Solution

It is well known that VTNC undergoes multimerization when it interacts with a number of ligands or through immobilization [9]. Therefore, it was of interest to investigate whether Cyr61 interacts with SMTB 1–44 in solution through isothermal titration calorimetry (ITC). As a control, binding of PAI-1 to SMTB 1–44 was measured by ITC with the results shown in Figure 4, A and B. Fitting of the observed enthalpies to a single-site binding model revealed a \( K_D \) of \(<1.0 \text{ nM} \) for PAI-1 binding to SMTB 1–44. Estimation of the dissociation constant is limited by the parameter \( c = K_a [P] \), where \( K_a \) is the association equilibrium constant and \([P]\) is the protein concentration in the calorimeter cell. Measurement of the equilibrium constant is considered unreliable when the value for \( c \) exceeds 1000 [28]. The binding reaction was exothermic, with an enthalpy change \( \Delta H \) of -24 kcal/mol for

| Table 2. Kinetics of PAI-1 interactions with SMTB 1–44. |
|---------------------------------------------------------|
| \( k_{a1} (M^{-1}s^{-1}) \) | \( k_{d1} (s^{-1}) \) | \( K_D (\text{pM}) \) |
| SMTB 1–44 | 2.312 x 10^6 | 0.00010 | 43.25 |

Responses were obtained by injecting stable mutant PAI-1 over immobilized SMTB 1–44 for 90 seconds at a flow rate of 30 \( \mu \text{l/minute} \). Data were derived from \( k_{a1} \) and \( k_{d1} \) and fitted using the Langmuir (1:1 binding) equation. Kinetic values obtained from the sensograms presented in Figure 3D.

doi:10.1371/journal.pone.0009356.t002

Figure 4. Cyr61 does not interact with SMTB 1–44 domain in solution. (A) Isothermal titration calorimetry for stable mutant PAI-1 interaction with SMTB 1–44. Base line-adjusted heats per injection of SMTB 1–44 (10 \( \mu \text{M} \)) into PAI-1 (1.0 \( \mu \text{M} \)). (B) Molar enthalpies per injection for PAI-1 interaction with SMTB 1–44. Filled circles, measured enthalpies; solid line, fit of experimental data to a single-site binding model. Thermodynamic parameters: \( \Delta H = -24 \pm 1.34 \text{ kcal/mol} \). (C) Base line-adjusted heats per injection of SMTB 1–44 (10 \( \mu \text{M} \)) into Cyr61 (1.0 \( \mu \text{M} \)). (D) Molar enthalpies per injection for SMTB 1–44 interaction with Cyr61 where no heat exchange is observable. Filled circles, measured enthalpies.
doi:10.1371/journal.pone.0009356.g004
binding of serpin to SMTB1–44. In agreement with the results obtained by gel filtration chromatography, as well as published structural studies [15–20], the stoichiometry of the binding (n = 0.77±0.01) was consistent with the binding of a single PAI-1 molecule to each molecule of the SMTB1–44 domain [15–20]. On the other hand, no observable heat was produced when SMTB1–44 was titrated with Cyr61 in a similar manner (Figure 4, C and D).

**Competitive ELISA**

Because ITC may not detect small heat changes that may occur in some protein interactions when studied at a given concentration [28], a second technique based on competitive ELISA [29] was employed in an attempt to estimate the relative reactivity of Cyr61 for VTNC and SMTB1–44 in solution. Increasing concentrations of either monomeric VTNC, heat-modified (55°C, 1 hour) monomeric VTNC, multimeric VTNC, SMTB1–44, and ixolaris (control) were co-incubated with a constant concentration of Cyr61 (30 nM) on multimeric VTNC-coated wells and assessed for ability to compete for binding of Cyr61 to immobilized VTNC. Figure 5 shows that monomeric VTNC at 50 μg/ml reacts weakly if at all with Cyr61, while heat-modified monomeric VTNC becomes reactive for Cyr61 at 15 μg/ml. On the other hand, multimeric VTNC at 15 μg/ml inhibited >50% of Cyr61 binding, while SMTB1–44 produced a similar effect at high concentrations (30 μg/ml, 6 μM). Ixolaris did not affect Cyr61 interaction with immobilized VTNC.

**Cyr61 Prevents Interaction of uPAR with Vitronectin**

The SMTB domain mediates integrin αβ3-, uPAR-, and PAI-1-mediated binding to VTNC [15–18,30]. More precisely, the domains of SMTB1–44 that interact with PAI-1 overlap extensively with those involved in the interaction with uPAR and occur independently of the integrin-recognition RGD sequence [17,18,31]. Accordingly, it was of interest to verify whether Cyr61 might affect uPAR interaction with VTNC, using PMA-differentiated U937 cells that reportedly express uPAR [32–34]. Consistent with its SMTB1–44-binding properties, Cyr61 (1.5 μM) attenuates U937 adhesion to VTNC in ~40%, while stable PAI-1 mutant, which was used as a control, blocks adhesion in >90% (Figure 6).

**Discussion**

CCN family members are potent regulators of angiogenesis, chondrogenesis, and embryogenesis. More recently, novel CCN activities have been revealed, including their ability to induce apoptosis as cell adhesion substrates, to dictate the cytotoxicity of inflammatory cytokines such as TNF-α, and to promote hematopoietic stem cell self renewal [1–3]. Most of these activities are dependent on the association of CCN members with the cell surface and/or with the ECM. Therefore, understanding how CCN members interact with the matrix is a relevant aspect of this family of proteins. In this context, Cyr61 from 3T3 cell lysates binds to heparin-agarose beads in vitro [35], and CCN family members such as Cyr61/CCN1 and CTGF/CCN2 reportedly interact with heparin sulfate-containing proteoglycans (HSPG) including syndecan 4 and perlecan [36,37]. Decorin, byglican, fibronectin, integrins, and growth factors are other molecules that have been identified as ligands for this family of proteins [1–3].

In this report, we demonstrate by SPR and solid-phase binding assays that Cyr61 binds with high affinity to immobilized VTNC. This discovery helps us to understand why VTNC remains associated with the ECM, being an important extracellular component with wide tissue distribution [38]. VTNC plays a significant role in a number of physiological and pathological processes involving cell adhesion and migration, angiogenesis, wound healing, and regulation of the plasminogen activation system [12,13]. Interestingly, Cyr61 shares with VTNC a number of biologic activities, including interaction with αβ3 integrin, promotion of attachment of HUVEC when immobilized in a...
plastic surface, and pro-angiogenic properties [1–3]. Consistent with these in vitro findings, Cyr61 induces angiogenesis in vivo, and Cyr61-null mice suffer embryonic death primarily due to vascular defects in both placenta and embryo [39]. These observations provide clear evidence for a key physiological role for the Cyr61 in angiogenesis, as has been the case for VTNC [8]. In this context, VTNC and Cyr61 have been linked to malignant progression of cancers including breast [40], ovarian [41,42], and hepatocellular cancer [43], and both molecules are found in the lymph node [44–46]. Whether this association is coincidental or biologically relevant remains to be determined.

SPR and solid-phase binding assays show that Cyr61 interacts with immobilized SMTB1–44 domain [15–20], with a similar affinity calculated for VTNC. Notably, the SMTB1–44 domain has been identified as the functional region of VTNC that mediates its interaction with PAI-1, uPAR, and integrin αβ3/αβ5 [15–20,23]. These molecules play a critical role in angiogenesis, granuloma tissue formation, and wound healing. For example, αβ3 is highly expressed in human endothelial cells and has been shown to mediate human endothelial cell migration in vitro and in vivo [9–11].

uPAR also contributes to matrix remodeling and cell migration through direct interaction with VTNC by focusing plasmin activation to sites of cell attachment and, in complex with integrins, can transduce intracellular signals [47–49]. On the other hand, PAI-1 is the primary serpin of both tissue- and urokinase-type plasminogen activators leading to attenuation of fibrinolysis and regulation of angiogenesis [12,13,50]. Because competition experiments confirm that PAI-1 and Cyr61 share a similar binding site in the SMTB1–44 domain (Figure 3H), and as Cyr61 attenuates uPAR-mediated U937 adhesion to VTNC (Figure 6), we speculate that this interaction may affect the binding of other ligands to VTNC. In fact, the domains of SMTB1–44 that interact with PAI-1 overlap extensively with those involved in the interaction with uPAR [17,18,31]. Structural data also indicate that the RGD sequence (residues 45–47 of the SMTB) is positioned close to PAI-1, leaving insufficient space for the RGD sequence to bind to integrins [51].

ITC experiments did not detect Cyr61 binding to the SMTB1–44 domain in solution, and competitive ELISA showed that monomeric VTNC reacts weakly if at all with Cyr61; however, modified monomeric VTNC displays higher reactivity, suggesting that cryptic epitopes for Cyr61 were exposed by heat treatment as reported for VTNC interaction with specific antibodies [14,29]. On the other hand, multimeric VTNC reacted strongly with Cyr61 in solution, possibly due to conformational changes due to selfassociation [14]. Further, SMTB1–44 effects were observed only at high concentrations (30 μg/ml; 6 μM), confirming that its interaction with Cyr61 displays low affinity that could not be estimated by ITC. These results are relevant, because in vivo VTNC exist in at least two distinct states and these forms have different binding properties [8]. In plasma, VTNC exists in a native, monomeric conformation that lacks exposure of conformationally sensitive epitopes. In contrast, VTNC purified from serum by heparin affinity chromatography in the presence of 8 M urea is highly multimerized and conformationally altered. Conformational change of VTNC also occurs upon binding to ligands such as heparin, thrombin-antithrombin, and complement C5b-7 or upon immobilization of VTNC in plastic surface [8,14,32]. Further, during tissue injury or tumor growth, VTNC is recruited from the plasma into the ECM and assumes an active conformation through multimerization [14,30]. In other words, VTNC function is regulated by its conformation state, which has been identified as the cryptic C-terminal (heparin-binding site) [8,14,32] and N-terminal domains (including SMTB1–44) [29]. Differences in epitope expression between native and modified VTNC have been reported before. For example, the cryptic heparin-binding site is recognized by conformationally sensitive epitope antibody 6E6, while antibodies 13H1 and 16A7 that per se did not react with plasma VTNC recognize VTNC treated with heparin, cholesteryl, detergent, low pH, heating at 56°C, and by immobilization [14]. Moreover, modified VTNC reacted approximately 100-fold better than native VTNC with antibody MAB1244 and most notably with MAB153, an antibody directed against amino acids 1–40 of VTNC, which comprise the SMTB1–44 domain [29]. The same occurs for β-endorphin binding to VTNC, which affinity is remarkably increased by immobilization [53]. Therefore, it is plausible that multimerization of VTNC creates a binding site for Cyr61 that supposedly anchors the protein to the matrix.

It is important to recognize that the preparation of Cyr61 used in this study was expressed in Escherichia coli and obtained from a commercial source. This may introduce a potential limitation in our study, as bacteria-expressed Cyr61 may not display functionally important glycosylation that may be necessary for activity or take part in the folding of a particular (micro)domain of the protein. While we cannot exclude this possibility, E. coli-expressed Cyr61 induces proliferation of NIH3T3 cells with an ED50 of 2–3 μg/ml (Peprotech Inc. certificate of analysis). In addition, other proteins tested as controls in this study and produced either in E. coli or insect cells, such as IGFBP-1,-2, -3, and -4, did not interact with VTNC according to SPR experiments (Figure 1). Nevertheless, results presented here should be validated in the future with Cyr61 expressed by an eukaryotic expression system. Also, it cannot be excluded that Cyr61 interacts with an additional binding site in VTNC besides the SMTB1–44, as recently reported for PAI-1 [21,22]. Finally, whether Cyr61 and other CGN members associate with VTNC in vivo via a particular domain and whether this potential interaction has relevance to modulating the angiogenic tonus of the matrix are open questions that future studies will clarify.

Materials and Methods

Materials

Cyr61, IGFBP-1, -3 and -5 (expressed in E. coli), and IGFBP-2 and -4 (expressed in insect cells) were purchased from Peprotech (Rock Hill, NJ, USA). Native monomeric (70 kDa; product HVN) or denatured multimeric human VTNC (200 kDa; HVN-U), and PAI-1 (recombinant stable mutant form; product CPAI), were obtained from Molecular Innovations Inc. (Southfield, MI, USA). Human placenta soluble collagen Type I was from BD Biosciences (Bedford, MA, USA); Horm type I fibrilar collagen was from Chrono-log (Havertown, PA, USA) and laminin was from Upstate Biotechnologies (Charlottesville, VA, USA). Human VTNC and Cyr61 have been linked to malignant progression of angiogenesis, as has been the case for VTNC [8]. In this context, VTNC and Cyr61 have been linked to malignant progression of cancers including breast [40], ovarian [41,42], and hepatocellular cancer [43], and both molecules are found in the lymph node [44–46]. Whether this association is coincidental or biologically relevant remains to be determined.

Electrophoresis

Proteins were solubilized in LDS buffer and loaded in a 4–12% NU-PAGE gel with MES buffer using a NOVEX PowerPac350 apparatus. Proteins were stained with Coomassie Brilliant Blue G and destained in 15% methanol, 10% acetic acid. Molecular weight marker standards were: myosin (188 kDa), BSA (62 kDa), ...
glutamic dehydrogenase (49 kDa), alcohol dehydrogenase (38 kDa), carbonic anhydrase (29 kDa), myoglobin (19 kDa), lysozyme (14 kDa), aprotinin (6 kDa) and insulin, β chain (3 kDa).

Synthesis of SMTB\textsuperscript{1–44}, purification, refolding and mass spectrometry. SMTB\textsuperscript{1–44} domain (theoretical molecular weight 5,003.54) DQESCKGRCGETGFDV KKCQCDELCSSYQCSC-CTDYTAECKPOYT synthesis was carried out on a model 433A peptide synthesizer (Applied Biosystems, Inc., Fullerton, CA, USA) using solid-phase, Fmoc (9-fluorenylmethoxycarbonyl) peptide synthesis methodology with HBTU 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate); NMP, 1-methylpyrrolidine-2-one activation. All cysteine residues were trityl protected. The Fmoc groups were removed from the N-terminal amino group of the resin-bound peptide with 20% 4-methylpyridine in NMP. Deprotection/ cleavage from the resin was carried out with TFA/thioanisole/EDT (92:5:3, v/v/v) mixture at room temperature for 2.5 hours. The linear SMTB\textsuperscript{1–44} was purified by RP-HPLC on a Gemini C18 (21.2 mm × 250 mm) column (Phenomenex, Torrance, CA, USA) utilizing water/ acetonitrile gradient. The peptide was refolded as previously described [16]. Refolded material was purified by RP-HPLC under conditions used for the linear form. The final, folded peptide showed the correct molecular mass of 5,003.00 Da. It was biologically active based on its interaction with PAI-1 (see Results).

SPR Analysis

All SPR experiments were carried out in a T100 instrument (Biacore Inc., Uppsala, Sweden) following the manufacturer’s instructions. The Biacore T100 evaluation software was used for kinetic analysis. Sensor CM5, amine coupling reagents, and buffers were also purchased from Biacore Inc. (Piscataway, NJ, USA). HBS-P (10 mM Hepes, pH 7.4, 150 mM NaCl, and 0.005% (v/v) P20 surfactant) was used as the running buffer for all SPR experiments, which were carried out as described previously [54]. For immobilization and kinetic analysis, monomeric (10 μg/ml) or multimeric (10 μg/ml) VTNC in acetate buffer pH 4.5 were immobilized over a CM5 sensor via amine coupling, resulting in a final immobilization of 667.4 RU and 625.2 RU, respectively. In some experiments, VTNC was immobilized at 2851.4 RU. The SMTB\textsuperscript{1–44} domain (100 μg/ml) in acetate buffer pH 4.5) was immobilized as above at 337.2 RU. Kinetic experiments were carried out with a contact time of 90 seconds at a flow rate of 30 μl/minute at 25°C. Cyr61:VTNC complex dissociation was monitored for 600 seconds, and the sensor surface was regenerated by a pulse of 30 seconds of 20 mM HCl at 30 μl/minute. Blank flow cells were used to subtract the buffer effect on sensorgrams. After subtraction of the contribution of bulk refractive index and nonspecific interactions with the CM5 chip surface, the individual association (k\textsubscript{a}) and dissociation (k\textsubscript{d}) rate constants were obtained by global fitting of data using the two-state reaction (conformational change) interaction model using BIAevaluation\textsuperscript{TM} (Biacore, Inc.) [27];

\[
\begin{align*}
kal & \quad ka2 \\
\text{Cyr61} + \text{vitronectin} & \leftrightarrow (\text{Cyr61}: \text{vitronectin}) \times \leftrightarrow \text{Cyr61}: \text{vitronectin}
\end{align*}
\]

\[
kd1 \quad kd2
\]

Values were then used to calculate the dissociation constant (k\textsubscript{d})

\[
K_D = kd1 kd2 / ka1 (ka2 + kd2)
\]

The values of average squared residual obtained were not significantly improved by fitting data to models that assumed other interactions. Conditions were chosen so that the contribution of mass transport to the observed values of k\textsubscript{d} was negligible. Also, models in the T100 evaluation software fit for mass transfer coefficient to mathematically extrapolate the true ka and kd.

Solid-Phase Binding Assays

Monomeric or multimeric human VTNC (50 μl, both at 0.5 μg/ml in PBS, pH 7.4; 25 ng/well), or SMTB\textsuperscript{1–44} (50 μl, 50 μg/ml in PBS, pH 7.4; 2.5 μg/well) were immobilized overnight at 4°C in a flat-bottom 96-well microtiter plate (Immulon 2HB; Thermo Electron Co., Milford, MA, USA). Wells were washed with 2×200 μl PBS and blocked with PBS-0.4% v/v Tween 20 (PBS-T) for 2 hours at room temperature (RT). Cyr61 (50 μl, 0–1 μM diluted in PBS-T) was added to the wells for 90 minutes. Wells were washed in PBS-T and incubated for 1 hour with anti-Cyr monoclonal antibody (100 μl, 1 μg/ml in PBS-T). After 1 hour, wells were washed and incubated with alkaline phosphatase-coupled anti-mouse antibody (100 μl, 1:5000 in PBS-T). After washing, 200 μl of p-nitrophenol phosphate liquid substrate system (Sigma-Aldrich, St. Louis, MO, USA) was added to the wells, and the reactions were performed at 405 nm. In all experiments, a curve containing Cyr61 (0–1 μM) was added in parallel to wells that had not been coated to estimate nonspecific binding, which was typically less than 5% of total binding at the highest Cyr61 concentration (1 μM). The app k\textsubscript{a} values for Cyr61:VTNC or Cyr61:SMTB\textsuperscript{1–44} interactions were calculated by nonlinear regression analysis of the binding data according to the Langmuir isotherm equation using GraphPad Prism 3.0 (GraphPad Software, Inc., San Diego, CA, USA). Experiments were performed in quadruplicate or quintuplicate and repeated three times.

Specificity

Human multimeric VTNC (50 μl, at 0.5 μg/ml in PBS, pH 7.4; 25 ng/well); fibrillar collagen type I Horm (50 μl, 1 μg/ml in PBS, pH 7.4; 50 ng/well), recombinant tiscolaris (50 μl, 1.5 μg/ml in PBS, pH 7.4; 75 ng/well); soluble collagen type I or laminin (50 μl, 2 μg/ml in PBS, pH 7.4; 100 ng/well) were immobilized overnight as above. Wells were washed with 2×200 μl PBS-T and blocked with PBS-T for 2 hours. Then, Cyr61 (50 μl, 50 nM, in PBS-T) was added to the wells for 90 minutes. Reactions were followed as described for solid-phase binding assays.

Competition Assays for PAI-1 and Cyr61 Binding to SMTB\textsuperscript{1–44}

For competition experiments, SMTB\textsuperscript{1–44} (50 μl, 25 μg/ml in PBS, pH 7.4; 1.25 μg/well) was immobilized overnight, the wells were washed and blocked with PBS-T for 2 hours. In eppendorf tubes, Cyr61 (30 nM) and increasing concentrations of stable mutant PAI-1 (0, 50, 500 nM) or tisolaris (500 nM) were combined in PBS-T. Then, 50 μl of this mixture were added to SMTB\textsuperscript{1–44} coated microwell plates for 90 minutes. Alternatively, PAI-1 was added to the plates for 30 minutes, washed three times, followed by addition of Cyr61 (30 nM). Cyr61 bound to SMTB\textsuperscript{1–44} was estimated as described for solid-phase binding assays.

Binding of PAI-1 to SMTB\textsuperscript{1–44} by Gel Filtration

This was performed using a Pharmacia Superdex peptide PC 3.2/30 column (3.2×300 mm), 2.4 ml bed volume, assembled in Akta Purified equipment (Amersham-Pharmacia Biotech, Piscataway, NJ, USA). Column optimal separation range is 100–7000 Da, with exclusion limit 20,000 Da. Column was equilibrated in
were calculated according to:

\[ Q = \theta M \Delta H V_0 \]  

where \( Q \) is the total heat content of the solution contained in the cell volume \( V_0 \), at fractional saturation \( \theta \), \( \Delta H \) is the molar heat of ligand binding, \( n \) is the number of sites, and \( M \) is the bulk concentration of macromolecule in \( V_0 \). The binding constant, \( K_a \), is described as:

\[ K_a = \theta / (1 - \theta) [X] \]

where [X] is the free concentration of ligand.

The free-energy \( (\Delta G) \) and entropy term \( (-T \Delta S) \) of association were calculated according to:

\[ \Delta G = -RT \ln(K_a) \]  
\[ \Delta G = \Delta H - T \Delta S \]

Competitive ELISA

Interaction of Cyr61 with distinct forms of VTNC or SMTB \(^{1-44}\) was investigated by competitive ELISA as described [29]. Briefly, microtiter wells were coated with multimeric VTNC (50 μM, 0.5 μg/ ml in PBS overnight at 4°C; 25 ng/well), and nonspecific binding sites blocked with PBS-T for 2 hours at RT. Wells were pre-incubated for 90 minutes with a mixture containing Cyr61 (30 nM) and different forms of VTNC or SMTB \(^{1-44}\) (concentrations indicated in the Figure). VTNC-bound Cyr61 was estimated as described for solid-phase binding assays.

Cell Culture

U937 (myelomonocytic cells) were obtained from American Type Culture Collection (Rockville, MD, USA) and were cultured in suspension RPMI-1640 medium (Invitrogen) containing fetal calf serum (FCS) 10% (v/v), penicillin (100 U/ml), and streptomycin (100 μg/ml) in a humidified incubator at 37°C with 5% CO₂. One day before the experiments, U937 cells were washed and resuspended in RPMI-1640 with 10% FCS (~300,000 cells/ml) and differentiated with PMA (50 nM) as reported [32–34]. Differentiated U937 cells which were attached to the plastic were briefly trypsinized, washed 3 times (5 minutes, 1000 xg), and resuspended in RPMI 1640 without additions (herein referred as RPMI). Cells (600,000/ml) were loaded with calcine-AM (2 μM), for 45 minutes under rotation (at RT) and washed three times. Cells were re-suspended in RPMI (no additions) to a concentration of 600,000/ml and used for cell adhesion assays as below.

U937 Cell Adhesion to Vitronectin

Multimeric VTNC (2 μg/ml in PBS, 50 μl/well, 100 ng/well, in quintuplicate) was added to Microfluor 2 black flat-bottom high-binding 96-well plates for fluorescence applications (Thermo Electron Co., Milford, MA, USA) and immobilized overnight at 4°C. Wells were washed three times with PBS, blocked with gelatin 0.5% (w/v) for two hours, and washed with RPMI (no additions). Then, 50 μl of Cyr61 or stable mutant PAI-1 (both 1.5 μM in RPMI no additions) were added to the wells and incubated for 60 minutes at RT, followed by washing with RPMI (no additions). Fifty μl of calcine-labeled U937 cells were added to the VTNC-coated plates (30,000 cells/well) and incubated for 120 minutes at 37°C, 5% CO₂. Plates were then inverted and washed with RPMI (no additions) three or four times, and fluorescence was measured with excitation wavelength at 490 nm and emission wavelength at 520 nm using a SpectraMax Gemini XPS Microplate reader (Molecular Devices, Sunnyvale, CA, USA). Fluorescence produced by cells attached to VTNC in the absence of Cyr61 or PAI-1 was set as 100% adhesion; adhesion to wells coated with gelatin only was negligible (<1% of total binding) and was set as 0% adhesion.

Serine Protease Inhibition Assays

All assays were performed at 37°C in triplicate [55]. Cyr61 (300 nM) was pre-incubated with each enzyme tested for 10 minutes before the addition of the corresponding substrate. All enzymes used were of human origin, purified or recombinant. Thrombin, α-chymotrypsin, trypsin, and chymase were purchased from Sigma, β-tryptase was purchased from Promega (Madison, WI, USA), factor Xa was purchased from EMD Biosciences (La Jolla, CA, USA), factor XIIa was purchased from Haematologic Technologies Inc. (Essex Junction, VT, USA), kallikrein was purchased from Fitzgerald Industries International (Concord, MA, USA), elastase was purchased from Elastin Products (Owensville, MO, USA), uPA and tPA from Molecular Innovations (Southfield, MI, USA), matryptase from R&D Systems (Minneapolis, MN, USA), and sequencing-grade trypsin was purchased from Roche (Chicago, IL, USA). The amount of enzyme used in each assay and the corresponding buffer are as follows: for elastase (0.01 nM) and chymase (1.8 nM), 50 mM Hapes buffer pH 7.4, 100 mM NaCl, 0.01% Triton X-100; for trypsin (0.25 nM) and α-chymotrypsin (0.05 nM), factor XIIa (1.2 nM) and thrombin (0.01 nM), 50 mM Tris pH 8, 150 mM NaCl, 20 mM CaCl₂, 0.01% Triton X-100; for β-tryptase (0.27 nM), 50 mM Tris pH 8, 50 mM NaCl, 0.05% Triton X-100; for kallikrein (0.8 nM), matryptase (1.2 nM), and plasmin (0.25 nM), 20 mM Tris pH 8.5, 150 mM NaCl, 0.02% triton X-100; for factor Xa (0.8 μM), 20 mM Tris pH 8, 200 μM NaCl, 5 μM CaCl₂, 0.1% BSA; for uPA (0.7 nM) and tPA (0.06 nM), 20 mM Tris pH 8.5, 0.05% Triton X-100. The substrates used were Suc-Ala-Ala-Pro-Val-AMC for elastase, Boc-Asp-Pro-Arg-AMC for thrombin and plasmin,
Boc-Gln-Ala-Arg-AMC for trypsin and uPA (Siga), Boc-Phe-Ser-Arg-AMC for b-tryptase, Suc-Leu-Leu-Val-Tyr-AMC for chymase (Bachem, King of Prussia, PA, USA), Suc-Ala-Ala-Pro-Val-AMC for a-chymotrypsin (EMD Biosciences, La Jolla, CA, USA), methylsulfonyl-D-cyclohexylalanyl-Gly-Arg-AMC acetyl for factor Xa, kallikrein, matryrsadec, factor XIIa, and iPA (American Diagnostica Inc., Stamford, CT, USA). All substrates were used in 250 mM final concentration in all the assays. Substrate hydrolysis rate was followed in a Spectramax Gemini XPS 96-well plate fluorescence reader (Molecular Devices) using 365 nm excitation and 450 nm emission wavelength with a cutoff at 435 nm.

Statistical Analysis
Experiments were performed three times in quadruplicate or quintuplicate, and results are expressed as means ± SEM. Statistical significance was determined using one-way ANOVA (Bonferroni multiple post-hoc test comparison) using GraphPad Prism 5.01 software. Significance was set at P≤0.05.

Acknowledgments
We thank Dr. Jose M. C. Ribeiro for support and NIAID intramural editor Brenda Rae Marshall for assistance. Because IMBF, JFA, and JL are government employees and this is a government work, the work is in the public domain in the United States. Notwithstanding any other agreements, the NIH reserves the right to provide the work to PubMedCentral for display and use by the public, and PubMedCentral may tag or modify the work consistent with its customary practices. You can establish rights outside of the U.S. subject to a government use license.

Author Contributions
Conceived and designed the experiments: IF. Performed the experiments: IF MK JFA. Analyzed the data: IF MK JFA. Contributed reagents/materials/analysis tools: IF. Wrote the paper: IF MK JFA JL.

References
1. Brigstock DR (1999) The connective tissue growth factor/cysteine-rich 61/ nephroblastoma overexpressed (CCN) family. Endocr Rev 20: 189–206.
2. Leak A, Abraham DJ (2006) All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 119: 4003–4010.
3. Holbourn KP, Acharya KR, Perbal B (2006) The CCN family of proteins: structure-function relationships. Trends Biochem Sci 31: 461–473.
4. Bach LA, Heady RJ, Norton RS (2005) IGF-binding proteins—the pieces are falling into place. Trends Endocrinol Metab 16: 228–234.
5. Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23: 824–855.
6. Mohan S, Baylink DJ (2002) IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol 175: 19–31.
7. Nam T, Moralez A, Clemmons D (2002) Vitronectin binding to IGF binding protein-5 (IGFBP-5) alters IGFBP-5 modulation of IGF-I actions. Endocrinology 143: 30–36.
8. Preissner KT (1991) Structure and biological role of vitronectin. Annu Rev Cell Biol 7: 275–310.
9. Brooks PC, Clark RA, Cheres D (1994) Requirement of vascular endothelial growth factor for angiogenesis. Science 264: 569–571.
10. Kleinman HK, Philip D, Hoffman MP (2003) Role of the extracellular matrix in morphogenesis. Curr Opin Biotechnol 14: 526–532.
11. Hynes RO (2007) Cell-matrix adhesion in vascular development. J Thromb Haemost 5 Suppl 1: S1–S2.
12. Della C, Loskutoff DJ (2005) Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 93: 631–640.
13. Cale JM, Lawrence DA (2007) Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent. Curr Drug Targets 8: 971–981.
14. Stockmann A, Hess S, Declerck P, Timpl R, Preissner KT (1995) Multimeric heparin. Identification and characterization of conformation-dependent self-association of the adhesive peptide. J Biol Chem 270: 22874–22882.
15. Okumura Y, Kamikubo Y, Correa SA, Wang J, Kiscda T, et al. (2002) Kinetic analysis of the interaction between vitronectin and the urorokinase receptor. J Biol Chem 277: 9395–9404.
16. Kamikubo Y, Kroon G, Correa SA, Dyson HJ, Loskutoff DJ (2006) The reduced, denatured somatomedin B domain of vitronectin refolds into a stable, biologically active molecule. Biochemistry 45: 3297–3306.
17. Zhou A, Huntington JA, Pannu NS, Carroll RW, Reader RJ (2003) How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol 10: 541–544.
18. Deng G, Correa SA, Wang S, Rosenberg S, Loskutoff DJ (1996) Is plasminogen activator inhibitor-1 the molecular switch that governs urorokinase receptor-mediated cell adhesion and release? J Cell Biol 134: 1563–1571.
19. Kjaergaard M, Vangelust IA, Andersen BS, Mather T, Ribeiro JM (2002) Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex. Blood 99: 3602–3612.
20. Francheschetti IM, Seydel KB, Monterio RQ (2008) Blood coagulation, inflammation, and malaria. Microcirculation 15: 81–107.
21. Morton TA, Myakha DG, Chakken EM (1995) Interpreting complex binding kinetics from optical biosensors: a comparison of analysis by linearization, the integrated rate equation, and numerical integration. Anal Biochem 227: 176–185.
22. Leavitt S, Freire E (2001) Direct measurement of protein binding energetics by isothermal titration calorimetry. Curr Opin Struct Biol 11: 560–566.
23. Seifert D (1995) Evidence that conformational changes upon the transition of the native to the modified form of vitronectin are not limited to the heparin binding domain. FEBS Lett 368: 155–159.
24. Seifert D, Giambone G, Wapner NV, Binder BR, Loskutoff DJ (1994) The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J Biol Chem 269: 2659–2666.
25. Huo Q, Zhou A, Lin L, Mazza AR, Pary RC, et al. (2000) Crystal structures of two human vitronectin, urorokinase and urorokinase receptor complexes. Nat Struct Mol Biol 15: 422–423.
26. Nusrat AR, Chapman HA, Jr. (1991) An autocrine role for vitronectin in phorbol ester-mediated differentiation of myeloid cell lines. J Clin Invest 87: 1091–1097.
27. Deng G, Correa SA, Hu G, Czekay RP, Loskutoff DJ (2001) Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol 189: 23–33.
28. Rovera G, Sampoli D, Danusky C (1979) Human promyelocytic leukemia cells in culture differentiate into macrophage-like cells when treated with a phorbol diester. Proc Natl Acad Sci USA 76: 2779–2783.
29. Yang GP, Lai LF (1991) Cyr61, product of a growth factor-inducible immediate early gene, is associated with the extracellular matrix and the cell surface. Cell Growth Differ 2: 351–357.
30. Nishida T, Kubota S, Fukunaga T, Kondo S, Yosimichi G, et al. (2003) CTGF/Hcs24, hypertrophic chondrocyte-specific gene product, interacts with perlecan early gene, is associated with the extracellular matrix and the cell surface. J Cell Physiol 196: 265–275.
31. Denoyers L, Arnott D, Pennica D (2001) VISP-1 binds to decorin and biglycan. J Biol Chem 276: 47599–47607.
32. Seifert D (1997) Constitutive and regulated expression of vitronectin. Histol Histopathol 12: 787–797.
33. Mo FE, Muncan AG, Chen CC, Stolz DB, Watkins SC, et al. (2002) Cyr61 (CCN1) is essential for placental development and vascular integrity. Mol Cell Biol 22: 8709–8720.
34. Auboe M, Offerens BV, Christensen A, Andreassen PA (2003) Vitronectin in human breast carcinomas. Biochim Biophys Acta 1638: 72–82.
35. Kenny HA, Kaar S, Soussens LM, Lenged E (2008) The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibrinogen. J Clin Invest 118: 1367–1379.
42. Carreiras F, Denoux Y, Staedel C, Lehmann M, Sicel F, et al. (1996) Expression and localization of αv integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Gynecol Oncol 62: 260–267.

43. Jaskiewicz K, Chasen MR, Robson SC (1993) Differential expression of extracellular matrix proteins and integrins in hepatocellular carcinoma and chronic liver disease. Anticancer Res 13: 2229–2237.

44. Bafetti LM, Young TN, Itoh Y, Stack MS (1996) Intact vitronectin induces matrix metalloproteinase-2 and tissue inhibitor of metalloproteinases-2 expression and enhanced cellular invasion by melanoma cells. J Biol Chem 271: 143–149.

45. Nip J, Shihata H, Loskutoff DJ, Cheres DA, Brodt P (1992) Human melanoma cells derived from lymphatic metastases use integrin αvβ3 to adhere to lymph node vitronectin. J Clin Invest 90: 1406–1413.

46. O’Kelly J, Chung A, Lemp N, Chumakova K, Yin D, et al. (2008) Functional domains of CCN1 (Cyr61) regulate breast cancer progression. Int J Oncol 33: 59–67.

47. Madsen CD, Ferraris GM, Andolf A, Cunningham O, Sidenius N (2007) uPAR-induced cell adhesion and migration: vitronectin provides the key. J Cell Biol 177: 927–939.

48. Wei Y, Czekay RP, Robillard L, Kugler MC, Zhang F, et al. (2005) Regulation of αvβ1 integrin conformation and function by urokinase receptor binding. J Cell Biol 168: 501–511.

49. Chavakis T, Kause SM, Yutzy B, Lijnen HR, Preissner KT (1998) Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood 91: 2305–2312.

50. McMahon GA, Petinckac E, Stefansson S, Smith E, Wong MK, et al. (2001) Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 276: 33964–33968.

51. Xiong JP, Strehle T, Zhang R, Joachimiak A, Frech M, et al. (2002) Crystal structure of the extracellular segment of integrin αvβ3 in complex with an Arg-Gly-Asp ligand. Science 296: 151–155.

52. Kost C, Stuber W, Ehrlich HJ, Pannekueck H, Preissner KT (1992) Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin’s heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation. J Biol Chem 267: 12098–12105.

53. Hádebrand A, Preissner KT, Muller-Berghaus G, Teschemacher H (1989) A novel β-endorphin binding protein. Complement S protein ( = vitronectin) exhibits specific non-opioid binding sites for β-endorphin upon interaction with heparin or surfaces. J Biol Chem 264: 15429–15434.

54. Calvo E, Tokunasu F, Marinotti O, Villeval JL, Ribeiro JM, et al. (2007) Aegyptin, a novel mosquito salivary gland protein, specifically binds to collagen and prevents its interaction with platelet glycoprotein VI, integrin α2β1, and von Willebrand factor. J Biol Chem 282: 26928–26938.

55. Kotyfakis M, Sa-Nunes A, Francischetti IM, Mather TN, Andersen JF, et al. (2006) Antiinflammatory and immunosuppressive activity of sialostatin L, a salivary cystatin from the tick Ixodes scapularis. J Biol Chem 281: 26298–26307.